Danese S, Dignass A, Laharie D, Limdi JK, et al. Mirikizumab is associated with rapid and sustained improvements in novel measures of bowel urgency in moderately-to-severely active ulcerative colitis: 28-week results from the LUCENT-URGE trial. J Crohns Colitis 2026;20:jjag049.
PMID: 42112567